News & Events
-
January 23, 2012
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials
Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion on the use of magnetic resonance imaging (MRI) to measure hippocampal volume as a tool to enrich recruitment into regulated clinical...... -
October 17, 2011
Critical Path Institute and Clinical Data Interchange Standards Consortium Announce Release of Data Standards for Alzheimer’s Disease Research
Critical Path Institute(C-Path)and Clinical Data Interchange Standards Consortium(CDISC) today announced the release of version 1.0 of the Alzheimer’s disease (AD) Therapeutic Area Standard(SDTM AD/Mild Cognitive Impairment User Guide). This was developed for the clinical research community to facilitate analysis and learning from clinical studies for treatment or prevention of AD.... -
December 10, 2010
Executive director of Critical Path Institute’s Coalition Against Major Diseases testifies before congress on Alzheimer’s disease progress
Marc Cantillon, MD, presents the critical role of public/private partnerships in creating innovative tools to advance the development of new Alzheimer’s disease... -
June 10, 2010
Coalition Against Major Diseases Introduces the First Combined Pharmaceutical Trial Data on Neuro-degenerative Diseases
A new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD)....